Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for Hypereosinophilic Syndromes (HES)
NCT00086658Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2004
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Proportion of subjects who achieve a total daily prednisone dose of <=10 mg for a period of 8 consecutive weeks at 36 weeks. Started Mar 2004; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT00086658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086658.